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Abstract 
Current tissue engineering therapies use macro-scale three dimensional (3D) scaffolds to treat 
tissue defects surgically. Uneven cell seeding and oxygen and media perfusion cause low cell 
viability in these macro-scale scaffolds. Microencapsulation, a technique of encapsulating cells 
in biocompatible polymers or hydrogels, has the potential to address these key issues, and 
therefore this technology has been used for numerous healthcare applications over the last two 
decades. Cell microencapsulation in hydrogels that mimic the tissue physiology and 
biochemistry has made it possible to use natural hydrogels like gelatin methacrylate (GelMA) to 
encapsulate cells in microspheres inside an oil emulsion, to serve as micron scale scaffolds to 
encapsulate cells for tissue engineering applications. Cell microencapsulation, however, has 
challenges with respect to the number of cell laden microspheres that can be achieved repeatedly 
with a consistent cell density per microsphere and their ability to achieve and maintain a high 
cell viability. This is the major impediment to the clinical translation of cell microencapsulation 
to treat tissue defects without surgery. In this work, cells were encapsulated within GelMA 
microspheres, ranging 30-250 micrometers in diameter using a 3D printing and replica casting-
molding approach. It is a non-clean room fabrication approach and hence a relatively 
inexpensive universal platform to encapsulate cells. Rheological properties of varying GelMA 
concentration were used to identify optimal concentration, flow rates of the GelMA and oil 
phases and the pressures required to achieve the desired size of microspheres with high 
repeatability. The success of this approach is demonstrated by high cell viability observed in the 
in vitro results. The use of 3D printing makes the fabrication of this microfluidic chip easy, 
 
 
inexpensive and accessible to biological researchers, and as a result, help lower the barrier of 
entry to the field of microencapsulation. 
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Chapter 1: Introduction 
 Scope 
This section comprises of an overview of the current challenges in fabrication techniques used 
widely in clinical settings for tissue engineering therapy. 
 
1.1 Introduction to tissue engineering  
Tissue engineering is a technique of using organ specific cells and seeding them onto support 
structures or scaffolds made out of biomaterials. These may be infused with bioactive factors that 
assist the viability, differentiation, and proliferation of cells when surgically implanted into the 
patient to develop functional organs[1]. Scaffolds or support structures are essential to hold the 
cells in a structure inside the body and also to provide a surface of attachment for the cells to 
grow and proliferate. Scheme 1 shows the basic concept of tissue engineering therapy. Stem cells 
are usually taken from a patient by a biopsy and they are cultured, expanded and seeded onto the 
macro scale (mm or cm or inch size) three dimensional (3D) scaffolds. These scaffolds are 
incubated in bioreactors that are units that help perfuse cell media, oxygen, and bioactive factors 
to assist cell viability, proliferation, and integration of blood supply or vascularization. It is 
important that the scaffolds are vascularized to ensure that the cells stay alive in the scaffold. 
This incubated scaffold is then surgically implanted into the patient where it should integrate 
with the host as the cells differentiate into the specific functional tissues.  Most of the approaches 
used in clinical tissue engineering therapy involve the use of macro scale scaffolds for seeding 
cells. These macro scale approaches involve two main challenges (i) uneven cell seeding 
throughout the 3D scaffold and (ii) inadequate oxygen and media perfusion throughout the 
scaffolds which could affect cell viability upon implantation[2]. 
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1.2 Overview of cell encapsulation in tissue engineering and current challenges. 
Seeding cells on scaffolds have challenges with achieving uniform cell distribution throughout 
the scaffold. The idea of cell encapsulation is to encapsulate cells in spheres made out of 
biocompatible polymers or hydrogels and seed these cell laden spheres on a three-dimensional 
(3D) scaffold. Cell encapsulation has proven to be an effective cell seeding technique to ensure 
even cell seeding throughout the 3D scaffold volume [3]. This scaffold can then be surgically 
implanted in the patient. The function of a scaffold is to degrade with time while holding the 
 
 
Scheme 1.Basic concept of tissue engineering therapy[3]. 
 
 
 
 
3 
encapsulated cells within the organ’s macro structure allowing them to differentiate and 
proliferate [4].Cell encapsulation in hydrogels has proved to be an effective cell encapsulation 
approach [3]. As shown in Scheme 2, tissue engineering functional organs use cell encapsulation 
technologies to ensure even cell distribution and density throughout the scaffold volume. Stem 
cells specific to the tissue type are taken from patients and are encapsulated in spheres made out 
of biodegradable polymers or hydrogels that mimic the in vivo environment. A large number of 
these cell laden spheres are then seeded on scaffolds and this helps ensure a better 3D 
distribution of cells throughout the scaffold volume. Since the cells are encapsulated in spheres, 
stacking multiple such cell laden spheres give a natural porosity to the macro structure of the 
scaffold. This allows better integration of the cells in vivo and ensures optimum room for 
vascularization of the construct as the encapsulating hydrogel degrades after implantation. 
Encapsulating cells at the macro (cm/mm or inch scale) and micron (less than 500µm) diameter 
spheres in different hydrogels like gelatin methacrylate (GelMA) and alginate have shown some 
success in the last decade in tissue engineering of liver, heart, cartilage, skin, and bone [5].  
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1.3 Importance of cell micro encapsulation: 
Cell encapsulation for tissue engineering therapy can be done both at the macro scale i.e. in 
spheres bigger than 500µm in diameter and also at the micron scale i.e. in spheres smaller than 
500 µm in diameter. Macro-encapsulation of cells in these hydrogels that mimic the in vivo 
environment to support the viability of cells serves as a good cell seeding strategy. However, 
scaffolds bigger than 300 μm in dimensions have issues of inadequate media and oxygen 
perfusion and inadequate vascularization leading to lower cell viability [6]. It has been 
demonstrated in the literature that it is essential to control the microsphere size to an optimal 
range to support maximum cell viability. It has been shown in the previous literature that for 
 
Scheme 2. Cell encapsulation applications in tissue engineering therapy[5]  
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microsphere sizes above 300µm a lower cell viability is generally observed [7]. Sawyer et al. 
suggested in their discussion that this could be due to the oxygen diffusion limit which inhibits 
cells from getting the necessary nutrition and causes low cell-viability [8]. A precise control over 
the size of these hydrogel microspheres plays a critical role in affecting the phenotypic 
characteristics like differentiation or induction or gene expression of the encapsulated cells 
making this a universal platform technology for stem cell therapy [8][9].Microencapsulation of 
cells facilitates the even cell seeding since the hydrogels that encapsulate these cells in micro 
spherical emulsions themselves act as micron scale scaffolds. Due to the micron scale of these 
hydrogel microspheres, they are easily injectable thus potentially eliminating the need for highly 
invasive surgery required to implant larger scaffolds to treat 3D visceral tissue defects [10]. 
These micron scale structures can be made out of a variety of biocompatible hydrogels with 
varying concentration of prepolymer solutions and hence varying degradation rates [11]. This 
formed the basis of selecting a micro-encapsulation approach for potential applications in tissue 
engineering. 
 
1.4 Existing micro encapsulation techniques and their drawbacks 
Microfluidic devices have been extensively used for a wide variety of cell applications. The 
ability to study the effects of the microenvironment on cell growth, viability and differentiation 
with precision has made microfluidics their own industry with a predicted market value of 
billions of dollars [12]. The existing technologies have increasingly used micro encapsulation 
due to the small scale encapsulation of cells for a variety of applications in immunology, drug 
testing, determining the effects of a variety of biophysical parameters on cell-signaling, motility, 
survival, and differentiation [13]. The popular devices used for micro-scale encapsulation of cells 
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often require clean room fabrication techniques that are either complex or prohibitively 
expensive. Most of these techniques use microfluidic devices for cell encapsulation [14][15]. The 
current challenges facing the microfluidic devices used for cell encapsulation on the market are 
the complexity of fabrication and their dedication to encapsulate limited cell types [16][17]. 
Another issue associated with the microfluidic chips that are currently used for cell encapsulation 
is the lack of flexibility of the experimental set up with respect to efficiency of sample collection, 
microsphere size repeatability, and the number of cells per microsphere [8]. Scheme 3 shows the 
existing technologies for micro encapsulation used in laboratory research. 
   
 
 
 
Scheme 3.Existing technologies for cell microencapsulation[5] 
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Bulk and hollow: In this approach, the cells are encapsulated in bulk hydrogel blocks or in 
hollow hydrogel fibers by pressurizing through a syringe nozzle or block casting of hydrogels. 
This is a macro-scale approach, however, can be used at a micron scale by 3D printing micron 
scale blocks of hydrogels laden with cells [5]. 
Micro molding: In these techniques, typically a master mold is fabricated using any lithography 
approach with the desired microstructures. The hydrogels laden with cells are pipetted into these 
microstructures, cross-linked and removed to yield the cell-laden microstructures [5]. 
Micro bead/T junction: These are principally microfluidic devices that have two-micron scale 
channels that intersect in a T junction. The microencapsulation occurs at the T junction cross 
section[5]. 
Microfiber: This technique uses a capillary based microfluidic design to generate micron-scale 
diameter fibers of cell laden hydrogels [5]. 
Oil drop method is a technique of dropping cell-laden GelMA balls into an oil well so that the 
cell laden GelMA balls up into spheres coated with a layer of oil. Another group of widely used 
popular microfluidic devices for cell encapsulation employ the oil drop methods that use clean 
room fabrication approaches to create hydrogel emulsions which make them prohibitively 
expensive [18]. The oil drop techniques used currently do not allow a precise control of emulsion 
morphology or the number of cells encapsulated per sphere.  
 
In this thesis work, a flow focusing T junction model is used. Flow focusing T-junction models 
are widely used in the synthesis of microspheres using a laminar flow of two immiscible phases 
[19][20]. A flow focusing T junction consists of two micron scale microfluidic channels that 
intersect at right angles to form a T shaped junction. One of the inlets is for an aqueous phase 
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which is usually the hydrogel laden prepolymer solution with cells. Scheme 3 shows the current 
flow focusing microfluidic devices and how they are used in cell encapsulation that allow 
encapsulating cells in micron scale spheres by controlling flow rates of the aqueous and the oil 
phases. The major concern with the existing T junction models was that the lipid phase or the oil 
phase used induced a very high shear stress on the hydrogel phase containing cells, which affect 
the cell viability that can be maintained [19][18]. For tissue engineering applications maintaining 
a high cell viability is of vital importance.  
 
 
 Regardless of the size of the resulting encapsulation constructs, the greatest limitation to the 
widespread use of microfluidic setups is their complexity of fabrication [21][22]. This is 
especially true for devices used for micron scale encapsulation of cells, which requires the use of 
traditional clean room fabrication techniques. Popular photolithography techniques using silicon 
 
Scheme 4.Microfluidic devices in cell encapsulation[56] 
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substrates have dimensional limitations and are restrictively expensive[23][16]. Fabrication 
techniques employ clean room fabrication approaches to create hydrogel emulsions which make 
them prohibitively expensive [2]. Even the oil drop techniques do not allow for a precise control 
of emulsion morphology or the number of cells encapsulated per sphere. Other fabrication 
approaches for microfluidic devices used for microencapsulation include silicon etching [24], 
mechanical micromachining [25], imprinting and hot embossing [26], x- ray photolithography, 
laser photo ablation [27], 3D soft lithography [28] and injection molding [29], all of which have 
very complicated and elaborate experimental set-ups [30]. In summary, a broad range of 
techniques have been used to make microfluidic devices that enable the formation of 
microspheres using hydrogel materials. Hydrogels have emerged as an ideal material for cell 
microencapsulation studies due to their resemblance to the native extracellular matrix [31]. 
However, factors such as the method of cross-linking, toxic concentrations of photo-initiators 
[32], porosity parameters and storage capabilities also influence cell viability under this approach 
[33]. Microfluidic devices for cell encapsulation using fluid flow focusing microfluidic devices 
have been used for numerous in vitro assays to study the viability and behavior of cells in micron 
scale scaffolds. These devices allow for a precise laminar flow of fluid phases with a wide range 
of viscosities, with the ability to manage their flow rates. Along with their dimensions on the 
micron scale, microfluidic setups may ensure emulsification of two distinct phases at the cross -
section of the two channels, resulting in the creation of micro-spherical emulsion structures may 
serve as micro-scale scaffolds if the appropriate materials are used. The lack of precise control of 
encapsulation dimensions makes this process rigid and inflexible during translation into animal 
models for clinical studies. Efforts to improve these draw backs have led to numerous impetus on 
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developing fabrication techniques alternative to clean room approaches to fabricate microfluidic 
chips and molds.  
 
1.5 Goal of the thesis work: The goal of this work was to engineer a universal microfluidic chip 
to enable the encapsulation of cells using a high resolution 3 D printing fabrication approach for 
the microfluidic mold to make the cell encapsulation process high throughput and ensure there is 
minimum process induced damage and sustained high cell viability. 
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Chapter 2: Experimental Design 
 
2.1 Methods and Materials 
This section elaborates on the hydrogel synthesis, device fabrication and cell culture protocols 
used in the experiments for both the non-cell and cell work.  
 
2.1.1 GelMA synthesis protocol 
10 grams of Type A Porcine gelatin were weighed and dissolved in 100ml PBS buffer in a three-
prong flask immersed partially in a water bath. The water bath is set to heat a three-prong flask 
with magnetic stirs both in, the bath and in the flask. The water bath is maintained at a 
temperature of 60-65°C. To remove the oxygen, rubber stoppers were used to block two out of 
the three outlets of the three-prong flask. One outlet was left uncovered to account for pressure 
buildup. One of the two rubber stoppers were punctured with a needle allowing argon gas to flow 
in at 10 PSI for 10 minutes to remove any oxygen introduced during the dissolution of the gelatin 
in the buffer. 8 ml of methacrylic anhydride was added very slowly using a 5 ml syringe needle 
through one of the rubber stoppers on the three-prong flask. The mixture is allowed to react for 3 
hours. After 2 hours 45 minutes 100 ml PBS buffer was warmed up to 60°C for about 15 minutes 
to dilute the reaction mixture. 3.5 liters of millipore water was set aside in a large beaker on a hot 
plate to warm up to 70°C. A 12-14 kDa cellulose membrane was suspended in this millipore 
water bath allowing it to open up for about 10 minutes. One side of the membrane was clamped 
and the reaction mixture was poured into the cellulose membrane, clamped up on both sides and 
suspended in the millipore water for 1 week. The millipore water was changed every 12 hours 
for this one week. The reaction solution was then stored in centrifuge tubes and frozen overnight 
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in a -80ºC freezer. These tubes were then put in a lyophilizer and allowed to dry for one week. At 
the end of the second week, the GelMA was ready to use to make solutions of different 
concentrations. Irgacure 2959 was added to these solutions as a cross-linking photo initiator [34]. 
 
2.1.2 Device fabrication 
The device was designed on Inventor, a CAD design software. There are two channels 
intersecting at right angles to form a T junction. The channel width was defined at 150μm and 
the channel height at 2mm.The mold base was a rectangle 8mm in length, 5mm in width and 
2mm in thickness. PDMS base and curing agent were hand-mixed well in the 4:1 ratio and 
degassed in a vacuum gasket for 30 minutes. The PDMS was poured on top of the mold and 
cured in an oven at 60°C for 3 hours to set it. After 3 hours, the PDMS was cut along the edge of 
the mold using an xacto knife and peeled out. The peeled portion if the PDMS was the negative 
of the mold, which was bonded face down to a glass slide using a plasma cleaner at Dr. Maroo's 
lab in Life Sciences Complex, Syracuse University. 
 
2.1.2.1 Design and fabrication of the 3D printed microfluidic device 
The negative mold was designed for channel dimensions of 150 μm for both horizontal and 
vertical channel width, 4 mm channel height for all channels, the mold base was 4 mm thick and 
the mold rim was 5 mm in height. The inlet and outlet rectangular chambers were defined at 
0.2234 inches x 0.28 inches (5.67436 mm x 7.112 mm). The chip was then connected to the 
inlets as shown in Figure 1. 
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To fabricate the microfluidic chip the CAD design was extruded and exported as a .stl file to the 
Cornell NanoBiotechnology Center (NBTC) at Ithica Cornell University, where it was 3D 
printed on a plastic like material called Vero-Clear using the ObJet 30 Pro 3D printer from 
Stratasys, Inc. This 3D printed showed a resolution of 16 microns for Vero Clear material (.0006 
in.) [35] allowing us to 3D print fine channels with ease. This mold as shown in Figure 2 (A) was 
shipped back to our lab at Syracuse Biomaterials Institute, where it was cleaned by submergence 
in a solution of KOH 25% w/v solution in 15ml DI water and manual cleaning of the 3D printing 
left overs. This cleaning process was repeated three to four times to obtain a clean mold that was 
ready for Poly Dimethyl Siloxane (PDMS) casting. PDMS was mixed in the 1:4 ratio of curing 
agent to base, poured on the mold, vacuum degassed and cured in an oven at 60˚C for 4 hours. 
Then this device was cut with a xacto knife along the edge of the mold and then peeled and 
plasma bonded to the glass slide as shown in figure 2(B) using the plasma cleaner facility. The 
 
 
(A)                                                                        (B) 
Figure 1 (A) 2D Front View and (B) 3D oblique view of the channel dimensions 
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plasma radiation time of 1minute 30 seconds was used for each chip at an oxygen pressure of 
10psi [36].  
 
 
2.1.3 Set up: 
The pump used to drive the encapsulation is the CorSolutions Pneu Wave dual channel pump. 
This pump operated on a pressure volume flow principle. The higher the pressure applied the 
higher the flow rate. The pump operates in a 0 -120 μl /min flow rate range for pressures from 0-
14.5 PSI. Figure 3 shows the entire experimental setup. The GelMA solution with and/or without 
cells flows through the tubing marked 1. The perfluorodecalin oil flows through the tubing 
marked 2 in figure 3. The GelMA phase enters the microfluidic chip at inlet marked 4 in figure 3. 
The oil phase enters the two inlets marked 3 in figure 3. The sample collection outlets are 
marked 5 on the figure. The samples (emulsions with microspheres) are collected through a tube 
marked 6 in figure 3. The samples are collected in a petri dish marked 7. These samples are then 
UV cross-linked.  
 
(A)                                                                (B) 
 
Figure 2. (A) 3D printed mold (B) Microfluidic device after replica molding and plasma 
bonding: (1) Inlet for GelMA phase (2) Inlets for oil phase (3) Outlet. 
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2.2 Non-cell emulsion experiments: 
To test the range of emulsions that could be achieved by this chip, solutions of different w/v 
concentrations of GelMA prepolymer were tested for their ability to form UV cross-linkable 
microspheres. 3%,5%,7%,8%,10% and 15% w/v GelMA prepolymer solutions were therefore 
made. The GelMA prepolymer solution flowed through the vertical channel as shown in Figure 2 
(B) (Inlet 1) in the results section of this work, while the oil phase was a fluorinated oil 
perfluorodecalin, which has been found to successfully encapsulate hydrogels and assist 
osteogenesis in previous research [37].The oil phase flows through the horizontal channels from 
both inlets as shown in  Figure 2 B (inlet 2) in the results section of this thesis. The two phases 
merged at the cross section of the T junction in the chip where the microspheres are formed 
inside oil emulsions. These emulsions containing microspheres then flow out through the exit 
channel and are collected out of a needle from the exit channel. The volume of a single emulsion 
is typically 20μl that contains around 4510 microspheres. The emulsions were collected as 
subsequent squirtings in a petri dish and irradiated with UV-light (Output power 850 mW, Omni 
 
1. GelMA phase flow path                                   5. Outlet for sample collection 
2. Perfluorodecalin oil phase flow path               6. Tube outlet for sample collection 
3. GelMA phase inlet                                           7. Petri dish for sample collection 
4. Inlet paths for oil phase 
Figure 3. Experimental set up 
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Cure S2000) for different exposure times corresponding to different concentrations of GelMA. 
To make the chip a universal platform for encapsulating all clinically relevant cell types, a 
threshold of the 250 x 250μm2 cross sectional area was implemented. This resulted in 
microspheres ranging from 30 μm to 250 μm for different flow rate ratios and concentrations, the 
specifics of which are listed in the results section of this literature. 
 
2.2.1 Viscometric characterization 
An AR-G2 Rheometer (TA Instruments, New Castle, DE) was used to obtain the viscosity at 
high shear of prepolymer solutions of varying GelMA concentrations. A parallel plate setup was 
used with a 40mm diameter steel geometry serving as the top plate. An implemental heating 
plate (522310.902 Peltier plate assembly) was used as the bottom plate to ensure the tests were 
performed at 37oC to replicate experiment conditions and prevent thermal gelation of the 
solutions. 2 ml of prepolymer solution was carefully pipetted at the center of the heating plate. A 
gap of 1.5 mm was maintained. The temperature was equilibrated for two minutes, after which 
the samples were subjected to a steady state flow procedure where the shear rate was ramped 
from 0.1 – 1000 s-1.   
  
2.2.2 Rheological Characterization  
An AR-G2 Rheometer (TA Instruments, New Castle, DE) with a parallel plate geometry (8 mm 
diameter) was used to determine the viscoelastic behavior of cross-linked hydrogel samples made 
from solution of different polymer concentrations.  
300 µl of each prepolymer solution was injected between two 18 x18 mm glass coverslips 
(Globe Scientific, Paramus, NJ) separated by a custom-printed PLA spacer with 1mm thickness. 
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Samples were then irradiated with UV for 60 seconds (Output power 850 mW, Omni Cure 
S2000). An 8 mm diameter biopsy punch (Robbins Instruments, Chatham, NJ) was used to cut 
out the hydrogel discs and detach them from the cover slips. The hydrogels were then incubated 
in ion-exchanged and distilled water at 37ºC for 24 hr prior to characterization to remove any un-
cross-linked gelatin prior to characterization. Rheological analysis was performed at room 
temperature using a gap size of 850 µm. Frequency sweeps (0.1-100Hz) were performed at 1% 
strain to identify the behavior of the storage and loss moduli of the constructs. The intersection 
point between the two data trends was noted.  
 
2.2.3 Injection experiment 
To test whether the obtained GelMA microspheres were stable when injected in and out of a 
syringe needle, 100µm and 150µm sphere sizes were tested. The pressure was scaled to obtain 
flow rates of 62.5µl/min for GelMA phase and 89.32µl/min to obtain an average sphere size of 
100µm repeatedly with good consistency. The flow rates of 72µl/min and 95.26µl/min were used 
to yield an average sphere size of 150µm with good consistency; both for 8% GelMA 
concentration in 13mL of PBS buffer. These samples were UV cross-linked (output power 850 
mW, Omni Cure S2000) for 90 seconds and suspended in DI water. A bright field image was 
taken before these spheres were sucked into the 23-gauge needle with a mean diameter of 
641.35µm. Then another image was taken after these spheres were injected out of the needle, 
after which these spheres were suspended in 20µl of DI water.  
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2.3 Cell Experiments: 
 
2.3.1 Step 1: Component sterilization: Autoclaving  
To ensure that the encapsulation occurs in a perfectly sterile environment we autoclaved all the 
tubing that came in any contact with the cell solution. The fittings and connectors like the luer 
locks, Y- junctions and inlet and outlet hoops were soaked in 100% cell culture grade ethanol in 
a biosafety hood under UV light to sterilize, as autoclaving damages them due to their lower 
temperature thresholds. The microfluidic chip was autoclaved as well to prevent any bacterial 
contamination of the GelMA emulsions within the chip. The autoclaving temperature was set at 
120°C, where the tubing was autoclaved for a 30-minute cycle and the oil autoclaved for another 
30/30 cycle. Autoclaving the tubing, devices and the oil is essential to ensure there is no bacterial 
contamination [38]. 
 
2.3.2 Step 2: Making GelMA prepolymer solution 
To make GelMA prepolymer solutions, a desired volume of buffer is filled in a centrifuge tube. 
For most of the experiments 13 mL of buffer were used to make the prepolymer solution. An 
appropriate amount (desired w/v concentration) of frozen GelMA polymer was weighed and 
dissolved in the buffer. To enable crosslinking 0.25% Irgacure 2959 photo initiator was added. 
This weight/volume ratio of 0.0025 was critical and has been found to work for previous 
research groups [2]. The centrifuge tube was then stored in an incubator at 37°C and left 
overnight to ensure that the GelMA dissolved completely and was adequately degassed before 
being sterile filtered. 
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2.3.3 Step 3: Making the Cell solution  
The GelMA prepolymer solution was sterile filtered using a non-pyrogenic Corning Incorporated 
28 mm micron membrane syringe filter (28 mm 0,20 SFCA) into a sterile centrifuge tube to 
ensure there is no bacterial or process induced contamination in the GelMA prepolymer solution. 
The vile containing the suspended cells is removed from the incubator and the old media is  
aspirated. The cells are then trypsinised.  
 
2.3.3.1 Cell Solution protocol 
Take 250 mL Saos-2 cell flask out of incubator. Under hood, use vacuum to remove DMEM 
(Dulbecco's Modified Eagle's Medium) media from the flask. Fill the flask with 10 mL of PBS 
(Phosphate Buffered Saline) to remove excess media. Vacuum out PBS. Add 5 mL of trypsin. 
Place flask back in incubator for 5 minutes. Remove flask after 5 minutes and tap the sides of the 
flask to detach the remaining cells from the bottom of the flask and into the trypsin solution. Add 
15 mL of media to the flask to counteract the trypsin. Mix well, and transfer the 
trypsin/media/cell solution into a 50 mL tube (should have 20 mL of solution). Take 10 µL of the 
solution and place it in one well of a 64 well plate. In the same well add 10 µL of Trypan blue 
dye. Mix and place 10 µL of the dye solution under the glass slide on the Hemocytometer. Take 
the 50mL tube and place it in the centrifuge across from a 50 mL tube filled with 20 mL DI 
water (for balance). Centrifuge at 200 rpm for 10 minutes. While centrifuge is running, count 
cells using 40x microscope and a clicker (ex. Yield 10 million cells). Also, while centrifuge is 
running, sterile filter 13 mL of GelMA (you will most likely get 11 mL post sterile filter) into a 
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15mL tube. Set GelMA aside. Retrieve 50 mL tube with solution in it from centrifuge and 
vacuum the media out (you should see the cells congregated at the bottom.) Add of media to the 
50mL tube with just the cells in it and mix (ex. this will give you 10 million cells per 1 mL of 
media.) Transfer this 1 mL of cells/media into the 15 mL GelMA tube and mix well [2].  
 
2.3.3.2 Osteosarcoma Cell culture 
Human osteosarcoma cells (Saos-2; ATCC) were used for cellular encapsulation studies[2].  
Saos-2 cells were cultured in Dulbecco’s Modified Eagle’s Media (DMEM; Life Technologies) 
supplemented with 1% penicillin-streptomycin (PS, Life Technologies), 1% GlutaMAX (G, Life 
Technologies), and 10% fetal bovine serum (FBS lot G12102, Atlanta Biologicals), within a 
humidified 37°C incubator containing 5% CO2 [2].  Prior to encapsulation, cells were grown to 
confluence and passaged using 0.25% trypsin-EDTA (Life Technologies). Cells were 
encapsulated in GelMA by mixing 1 mL of a cell solution density of approximately 6 million 
cells with 10 mL of 8% (w/v) GelMA solution[2]. The GelMA/cell solution was mixed 
thoroughly prior to encapsulation and was kept warm throughout the process. After 
encapsulation, oil emulsions containing GelMA microspheres were transferred into cell culture 
media. Media was changed on the emulsions every 2 to 3 days using standard cell culture 
procedures[2].  
 
2.3.4 Step 4: The encapsulation process 
The solution contain suspended Saos-2 cells in GelMA prepolymer solution was flowed through 
the vertical channel of my chip. The oil phase consists of a fluorinated oil perfluorodecalin[37] 
that is found to assist bone regeneration as well as found success in previous encapsulation 
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studies. The oil phase flows through both inlets of the horizontal channel. The two fluid phases 
intersect at the T junction where there is formation of the emulsion spheres. The cross –sectional 
area of the T junction is 150 x 150 μm2. This size allows creation of stable emulsion spheres 
ranging from 20 to 250 μm in diameter. This allows immense flexibility in the number of cells 
that we can encapsulate in each emulsion sphere. These emulsions flow out through the vertical 
exit channels where they flow out through a needle inserted in the exit channel. These emulsions 
were collected in petri dishes and then UV cross-linked for exposure times varying according to 
the concentration of GelMA in each solution. The UV crosslinking times observed for 
5%,7%,8%,10% and 15% w/v solutions were all under 120 seconds which is conducive for 
crosslinking GelMA without killing cells encapsulated within. These encapsulated cross-linked 
samples were then transferred to a 24-well plate in the biosafety hood. They are then stored in 
1mL complete DMEM media in the incubator to ensure cell viability before staining.  
 
2.3.5 Staining: 
2.3.5.1 Live/ dead staining:  
Live/Dead staining and image processing:   
The viability of cells was determined using a Live/Dead assay.  In order to determine cell 
viability, emulsions containing cell-laden spheres were submerged in media containing Calcein-
AM (1:2000 dilution; Corning) and ethidium homodimer (1:500 dilution; Life Technologies), 
and incubated at 37°C for 1 hour prior to imaging [2].  Emulsions were analyzed at 1 day, 1 
week, 2 week, and 3 week time points, respectively. 
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Raw .tiff fluorescent images were taken of the stained emulsions using a Leica DMI4000 B 
inverted microscope (Leica Microsystems GmbH), and were analyzed using open-source ImageJ 
(NIH) software. The images were tuned for brightness and contrast. 
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Chapter 3: Results and Discussion
 
3.1 Non-cell GelMA microsphere synthesis: 
Figure 4 (A) shows the microspheres obtained for flow rates of 35 μl/min for GelMA phase and 
50 μl/min for oil phase which generated microspheres of ~33 to 35 μm. The UV cross-linking 
time observed for different concentrations of GelMA solutions was recorded and reported in 
Figure 4 (B) Table 1. Through experiments, it was observed that it is possible to fabricate 
GelMA microspheres with an optimal UV cross-linking time and viscosity efficiently and with 
maximum repeatability for 5 to 15% w/v GelMA concentrations. It was observed that for less 
than 5% GelMA concentration, the UV cross-linking time required is over 3 minutes which 
would be lethal for encapsulating cells in these microspheres and it is also very difficult to 
crosslink lower than 5% w/v concentrations of GelMA. 
 
 
 
 
 
 
 
 
 
Different flow rate ratios of the GelMA phase and the oil phase yield microspheres of different 
mean sphere sizes. With this microfluidic chip, it was possible to create microspheres 35 to 250 
                     
(A)                                                                                   (B) 
Figure 4. (A) GelMA microspheres 35µm in mean diameter made from 8% (w/v) 
GelMA (Scale bar: 50 µm) and (B) Table 1. Representing UV crosslinking time for 
crosslinking microspheres made from different (w/v) concentrations of GelMA. 
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µm in diameter with maximum repeatability. Table 1. shows the different flow rates used for the 
GelMA phase and oil phase to obtain different sizes of microspheres. The standard deviation 
values are low indicating a high degree of uniformity achieved in the obtained microspheres. 
The results of this experiment indicate the range of GelMA concentrations that is optimal to 
effectively make injectable hydrogel microspheres to serve as scaffolds of micro scale that can 
potentially encapsulate all clinically relevant cell types. Figure 5 (A) Table 1 represents the 
average size of GelMA microspheres achieved with 8% (w/v) GelMA solution at varying flow 
rates. Each solution concentration flowed at three district flow rate ranges and it was observed 
that varying these values resulted in microspheres of distinct sizes. As an example, the following 
trends were observed for the 8% (w/v) GelMA phase and the standard oil phase respectively. For 
flow rates of 45.725 µl/min for GelMA phase and 75.68 µl/min for oil phase (8% w/v GelMA 
concentration), repeated microsphere mean size ~50 μm-corresponding to these flow rates. For 
flow rates of 65.27 µl/min for GelMA phase and 89.32 µl/min for oil phase (8% w/v GelMA 
concentration) repeated microsphere mean size ~100 μm corresponding to flow rates. For flow 
rates of 72.67 µl/min for GelMA phase and 93.76 µl/min for oil phase (8% w/v GelMA 
concentration) repeated microsphere mean size ~150 μm-corresponding to the flow rates. After 
repeating these trials, these values were found to be consistent.  
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3.2 Characterization of material properties: 
The hydrogel used for cell microencapsulation in this work was tested for different w/v 
prepolymer solution concentrations. The viscous and rheological properties of these prepolymer 
solutions were characterized. Figure 6 (A) represents the viscosity profiles of different (w/v) 
GelMA prepolymer solution concentrations. The viscosity varies as the shear rate on the parallel 
plate is varied from 1 to 1000 s -1. Non-cell experiment work was necessary to optimize 
conditions and characterize our materials. Physical characterization was centered on observing 
the hydrogel storage and loss moduli for different concentrations of GelMA. Figure 6 (B) 
represents the storage and loss modulus of an 8% (w/v) cross-linked hydrogel disc. This was 
done to approximate the stiffness of the matrix environment experienced by the cells once in 
          
                                                                           
(A)                                                               (B) 
Figure 5. (A) Table 2. Different mean microsphere sizes achieved using 
different flow rates and (B) Representative images of 50,100 and 150µm 
microspheres. Scale bar: 150µm 
50µm 
100µm 
150µm 
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their encapsulated form. Solution viscosity was a focal point of study [39] to identify the 
maximum concentration that could be used that would optimally flow through the setup at the 
high flow rates to be used, especially since the laminar flow was required to effectively form our 
microspheres. The temperature and the flow rates corresponding to this shear rate were 
determined to be the thresholds (minimum flow rate) required to form emulsions at these 
solution concentrations. To quantify the mechanical nature of microspheres made out of these 
pre-polymer solution concentrations, rheological characterization of the loss and compression 
modulus was done [40]. A comparison of the viscous and mechanical properties of varying w/v 
concentrations of GelMA helped us determine the w/v concentration range and narrow down on 
the GelMA concentrations that work best for cell encapsulation experiments that are discussed in 
the following section. 
 
 
 
 
 
 
 
 
Microspheres of specific dimensions were expected to show unique swelling behavior which is 
shown in Figure 7. Figures 7(i - iii) represent the swelling observed for 3 repeatedly achieved 
microsphere sizes using 8% (w/v) GelMA. It was observed that the microsphere with 50μm 
  
(A)                                                                    (B) 
Figure 6. (A) Viscosity profiles of different (w/v) GelMA concentration prepolymer 
solutions and (B) Storage and loss moduli for 8%(w/v) GelMA slab  
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initial mean diameter saw a 35.01% increase in diameter. Samples with a 100μm initial mean 
diameter saw a 16.54% increase in diameter, while the larger microspheres with a mean diameter 
of 150 μm initial mean diameter also saw a small increase in diameter but only of about 8.6% 
after complete swelling. For all tested samples, it was observed that the completely swelled state 
was reached after about 2 hours 30 minutes, after which no significant change in dimensions was 
observed. The stepwise mean %increase and standard deviations are listed in a table in the 
Appendix A Section C of this work.  
 
 
 
    
(A)                                                                           (B) 
                                                                                                
Figure 7(A) Swelling profiles: %increase in mean microsphere diameter as observed with 
time and (B) represents the before and after swelling images of 50,100 and 150µm mean 
sphere sizes. Scale bar :150µm 
 
 
 
(i) 
50µm 
(ii) 
100µm 
(iii) 
150µm 
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The overall range of microsphere diameter achievable with this microfluidic chip using this two-
variable experimental set up was ~30 to 250 μm. Figure 8 represents the before and after 
injection images for a 20 µl emulsion volume of 100 µm mean sphere size. There was no 
disruption of the microsphere size observed upon injection in and out through a 20-gauge needle. 
There was some disruption in microsphere shape observed upon injection through a 23-gauge 
needle for a mean microsphere size of 100µm. 
Figure 9 represents the average number of microspheres of   50,100 and 150 μm mean sphere size 
per μl of emulsion volume. The microspheres are laden in an oil emulsions which were ejected as 
20 microliter emulsions from the outlet of the microfluidic chip. This table and graph give an 
estimate of the number of microspheres obtained per unit volume of an emulsion.  
 
(A)                                                                                                           (B) 
Figure 8. (A) and (B) Before and after injection images of 100µm GelMA microspheres 
through a 20-gauge needle. Scale bar: 100µm 
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3.3 Cell Encapsulation experiments 
A solution concentration of 8% (w/v) GelMA was selected for all cell encapsulation work based 
on all these studies. The viscosity of this prepolymer solution was shown to exhibit laminar flow 
through the pump setup when at 37oC most efficiently, which is the required temperature to 
maintain cell viability. The UV exposure time required to cross-link the resulting microspheres 
was also low enough to ensure that this viability was maintained. The constructs also exhibited 
structural stability when incubated for three weeks. Figure 10 (A) shows a single emulsion sphere 
100 μm in diameter with cells encapsulated within. The image was taken after performing the cell 
encapsulation experiment when the microsphere was in media. The image is taken at 40x bright 
field using an inverted microscope. It was observed that larger microspheres encapsulated a greater 
number of cells. Figure 8 (A) and (B) shows ~28 cells encapsulated in a 100 μm sphere in media 
and oil respectively.
 
(A)                                                                             (B) 
Figure 9. (A) Graph and (B) Table 3. Representing average number of microspheres per µl of 
emulsion volume  
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Figure 11. (A) Represents the number of cells encapsulated in spheres of different sizes. The 
number of cells that can be encapsulated increases with an increase in the size of the 
microsphere. The 100 μm sphere as shown in Figure 11 (A) has around 28 cells encapsulated 
within. The cell concentration plays a key role in determining the cell encapsulation density per 
microsphere. The cell density that proved most effective was 6x106 cells per 1 ml cell media 
added to 11 ml i.e. 545,454 cells/ml GelMA prepolymer solution after sterile filtering. Different 
cell densities dictate how much volume of each microsphere is occupied. This also largely 
depends on the cell dimensions or the shear rate used. In this setup, we used Saos-2 cells which 
are approximately 8-10 μm in diameter [41]. Through our experiments, we identified that for cell 
densities greater than 545,454 cells per ml cause excess shear stress on the cells when they flow 
through the tubing that leads up to the device inlet. Figures 11 (A) and (B) represent the number 
of cells encapsulated per microsphere of different mean microsphere diameters. It is evident from 
the graph that as the mean microsphere diameter increases, the number of cells encapsulated per 
 
 
Figure 10. Single microsphere cell encapsulation images.100 μm sphere with cells 
encapsulated (A) in media and (B) in perfluorodecalin oil. Scale bar:100 μm 
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microsphere increase. A test of significance for correlation coefficient was performed on this 
data and it was found that there is a significant correlation between the microsphere mean 
diameter and the number of cells encapsulated. 
 
 
 
 
 
 
 
 
 
 
Figure 12 represents the %Viability of cells as observed for 100 μm spheres on Day 1, Day 7, 
Day 14 and Day 21. We observed a cell viability of 98.03% on Day 1 indicating that this process 
is fairly mechanically robust and biocompatible enough to not introduce a significant process 
induced damage or contamination. A viability of 93.75% on Day 7, 90.125% on Day 14 and 
81.25% on Day 21 was observed. The Figures 12 (i), (ii) and (iii) show the actual live /dead 
staining progression from Day 7 through Day 14 to Day 21. An ANOVA analysis was performed 
on this viability data which is listed in the Appendix A Section D section of this thesis, which 
reaffirms the visually obvious significant difference in the cell viability over the three week 
incubation period. Cell density plays a key role in determining the cell encapsulation density per 
microsphere. The cell density that proved most effective for our trails was 6x106 cells/mL of cell 
 
Figure11. (A) and (B)Table 4 and graph representing the average number of cells 
encapsulated per microsphere for different mean microsphere diameters 
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media added to 10mL GelMA prepolymer solution (11mL total). Different cell densities dictated 
how much volume of each microsphere was occupied. Limited process-induced damage was 
observed as cell viability remained close to 100% immediately following the procedure. 
Incubation over a three-week period showed that viability only decreased by ~20%. This shows 
that our encapsulated cell samples may be stored without the need for cryopreservation. Cell 
density was also shown to play a role in influencing cell viability. Densities higher than the 6 
million cell count was shown to cause a decrease in cell viability when encapsulated. Additional 
factors such as cell size and applied shear stress resulting from an increased cell density during 
the encapsulation procedure would be expected to play a role in cell viability when using other 
cell types. We can therefore assume that use of larger cell strains may exhibit a different viability 
profile as oppose the Saos-2 cell quantified for this work, and therefore we may need to optimize 
an appropriate cell density to achieve the similar viability statistics.  
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                           (i)Day 1                                         (ii)Day 7 
         
(iii)Day 14                                      (iv)Day 21 
 
Figure 12. (i)Day 1, (ii)Day 7, (iii) Day 14 and (iv) Day 21 viability (Scale bar 
:100µm). (A) Percentage viability as quantified on day 1, day 7, day 14 and 
day 21. (B)Table 5 representing average percentage viability and 
corresponding standard deviations.  
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Cell viability depends on the coordination between multiple parameters. The GelMA 
concentration used, the cell density used, the viscosity of the solution, and the temperature of the 
experimental set up. These were identified by experimenting with multiple GelMA 
concentrations, cell densities starting from 10 million cells and decreasing and adjusting the 
temperature and distance of the heating fan used to maintain the temperature of 37 °C. Also, it is 
essential to ensure that all the tubing, connection, devices and collection petri dishes are either 
autoclaved or sterilized by soaking them in 100% fill line ethanol to make sure that there is no 
contamination or process induced damage to the cells. 
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Chapter 4: Discussion, conclusion and future scope 
 
4.1 Discussion 
This section represents a comparison of existing cell micro encapsulation approaches and the 
improvement over the existing techniques in the aspects of fabrication approach, cell viability, 
high sample collection efficiency, high microsphere size repeatability and uniform number of 
cells laden per microsphere. The results presented in this work have shown a significant 
improvement over certain impediments to the existing cell micro encapsulation approaches over 
factors of (i) fabrication approach, (ii) cell viability, (iii) high sample collection efficiency, (iv) 
high microsphere size repeatability and (v) uniform number of cells laden per microsphere. The 
mold used to cast the microfluidic devices was fabricated using a 3D printing fabrication 
approach and PDMS casting and molding technique.  
 
4.2 Research approach  
The novelty of this design allows immense flexibility of the size of microspheres that can be 
made and used to encapsulate a varying number of cells per microsphere depending on the cell 
density used in your cell solution and the size of microspheres. Due to the small size of achieved 
microspheres, they are injectable and hence can potentially help eliminate the need for surgery 
[42].This engineered chip enables micron scale encapsulation of all clinically relevant cell types 
in emulsion spheres ranging 30 to 250 μm in size. Due to the small size and range of 
encapsulation, effective media and oxygen diffusion is possible, thereby showing enhanced cell 
viability as demonstrated in my results. The flexibility in choosing varying concentrations of 
GelMA to encapsulate cells allows control on properties like swelling and degradation of the 
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hydrogel microspheres. Also, there is control of parameters like viscosity and mechanical 
robustness of the used hydrogel concentrations. To support and hold the cells in place it is 
essential that they are seeded inside a support structure or a scaffold. Many times, cells do not 
get evenly seeded in the scaffold. The microspheres generated by this chip allow the creation of 
cell laden microsphere scaffolds which ensure adequate and even cell seeding all throughout the 
size of the injury or defect which needs the tissue engineered construct [43]. Due to their small 
size, these microspheres can be injected at the site of tissue injury without the need for imminent 
surgery. This exciting hypothesis is what has led to the application of microencapsulation 
approach for this work. 
 
This approach of micron scale encapsulation in hydrogel makes it a lot easier to preserve these 
micro-scale scaffolds in a normal well plate in an incubator instead of cryopreserving the 
construct. Cell viability is determined by a variety of parameters: toxicity and the amount of 
photo initiator [44], the degradation rate of encapsulating hydrogel, cell media and oxygen 
perfusion, porosity and interconnectivity of the scaffold, cryopreservation, storage requirements 
and the duration of storage [33][45]. The system designed in this work proposes a highly flexible 
and customizable technique to create hydrogel droplet scaffolds that resize all such parameters to 
help achieve enhanced cell viability. The PDMS based closed chip is made out of a 3D printing 
[46] and replica molding [47] approach which ramps up the ease of fabrication to your lab bench. 
Being an inexpensive polymer, you can make a large number of these chips and use them for 
encapsulation applications of various kinds of studies. This work presents an inexpensive 
microfluidic chip fabricated through 3D printing [48] followed by a replica casting and molding 
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technique [49]. The system designed proposes a highly customizable technique to create 
hydrogel droplet scaffolds that resize all parameters to help achieve enhanced cell viability.  
4.2.1 Fabrication approach: 
Popularly used microfluidic devices are manufactured using micromachining approaches with 
glass or silicon substrates. These micromachining approaches involve processes like chemical 
etching, lithography approaches that require a clean room for cleaning processes. Laser ablation 
approaches that need the use of high intensity laser beams to micro machine channels in different 
substrates. Other techniques like hot embossing, injection molding require thermoplastic 
substrates that have heat expansion related dimensional changes in the channels which impact 
the generated microsphere sizes and uniformity which varies with temperature [50]. In this work, 
the negative to the closed PDMS chip is made using a traditional 3D extrusion printing [51] and 
replica molding approach, which ramps up the ease of fabrication of multiple devices. In using 
Vero-clear plastic [52], an inexpensive polymer, multiple chips designs can be made on a budget 
and used for encapsulation applications for a wide variety of studies. It should be noted that for 
objectpro30 3d printer model RGD525, RGD430 and RGD450 [53] polymers can also be used in 
the printing process [35]. The use of PDMS as a casting agent facilitates the manufacture of 
multiple devices from a single print. After a careful deliberation of choice of 3D printing 
polymer and vertical resolution and ease of use and access, we decided to go ahead with the 
Stratasys Objet Pro30 model desktop size 3D printed to fabricate the microfluidic device used for 
microencapsulation in this work. The use of GelMA over synthetic hydrogels like PEG-DA has 
significantly increased over the past decade in cell microencapsulation applications [54] [55]. 
Natural hydrogels like GelMA are highly hydrated and porous like tissues making them a highly 
biocompatible choice to house cells. 
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4.2.2 Comparison cell viability in different micro encapsulation techniques:  
Multiple studies have been done to microencapsulate different cell lines and the viability of cells 
was monitored over different time frames.In using laminar flow model, for cell microencapsulation 
Kim et.al. demonstrated that the cell viability varied in proportion to the flow rate of the oil phase 
[56]. In that work, the viability was observed for over seven days and on 60% of the cell population 
was alive [56]. 
Kim et al. showed the viability of encapsulated fibroblasts in GelMA using a double flow focusing 
microfluidic chip design. The viability was monitored for over 10 days and was up to 80%.This 
approach revealed that cytotoxicity of the oil used for cell microencapsulation and position of cells 
during encapsulation process played a key role in determining process induced damage and 
corresponding viability monitored over a 10 day period [56].  
Weitz et al. demonstrated a 60% cell viability one day after encapsulation of microencapsulated 
bone marrow derived mesenchymal stem cells (BMSCs) in gelatin microspheres. Although the 
cells showed improved osteogenesis in vitro and in vivo in the encapsulated gelatin 
microspheres, the process induced damage was concerning [57][58].The results of this work 
show a far better cell encapsulation density per sphere and a wider range of repeatable 
microspheres achieved. 
Rossow et al. also demonstrated that after 1 day of encapsulation in  GelMA microspheres they 
achieved a viability of only 60% [57] whereas the approach of the research stated in this 
literature demonstrates a very high cell viability of 98.03% on Day 1 indicative of minimal 
process induced damage. 
Work done previously in the Soman lab by Sawyer et al. monitored the viability of Saos-2 cell 
encapsulated in 7%,10% and 15% w/v GelMA concentrations in 5 mm GelMA macro spheres. 
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The viability observed was ~70% for 7% GelMA concentration, and close to ~50% for 10% and 
~40% for 15% (w/v) GelMA concentrations. This is concerning because Saos-2 cells are a robust 
cancer cell line. If this approach were to be used to encapsulate clinically relevant stem cells 
which are more sensitive, a low viability would hamper successful translation for clinical tissue 
engineering therapy. In the discussion of their work Sawyer et al. mentioned that a low cell 
viability was expected as cells are encapsulated in 5 mm spheres that are beyond the diffusion 
limit of 300 µm as suggested in previous work [7][2]. A microencapsulation approach would 
help encapsulate cells within this suggested diffusion limit which forms the basis of the work 
presented in this literature. 
4.2.3 High sample collection efficiency and high microsphere size repeatability 
In a review by Rossow et al. problems associated with sample collection and the repeatability of 
the microsphere sizes are highlighted [56]. It was reported that the shear forces acting on the 
cells in the aqueous phase may cause process induced cell death which is a major concern. The 
transfer of the cell-laden micro gels into the oil phase must be as gentle as possible. This is not 
possible with higher flow rates and narrow device dimensions. The cytotoxic chemicals or the 
physical processes of pipetting used to break up emulsions can also cause cell death if the used 
chemicals are cytotoxic [58][57]. In this work, the channel height used is significantly taller than 
other designs which likely prevented high shear stress leading to low process induced damage. 
However, no simulation studies have been done to quantify the shear stress experienced by cells 
flowing through this device.   
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4.2.4 Repeatability of the number of cells encapsulated per microsphere 
Research by multiple groups has shown that encapsulation of cells in micro gels is a stochastic 
process and not all generated microspheres are laden with cells[59][60][61]. It was observed that 
around 86 out of 100 microspheres should be empty and only 1 droplet should contain more than 
one cells for single cell encapsulation[59][60][61]. The statistics vary and controlling the number 
of cells encapsulated per microsphere, has been a pressing challenge faced by microfluidic 
devices designed for cell microencapsulation [59][60][61]. 
The system designed in this work proposes a highly flexible and customizable technique to 
create hydrogel droplet scaffolds that resize all parameters to help achieve enhanced cell 
viability. The novelty of this design allows immense flexibility in the nature of the microspheres 
produced. Experiments have identified a range of parameters to relate emulsion size to both 
experimental flow rate and solution viscosity and concentration. This design enables varying the 
number of cells per emulsion sphere depending on the cell density of the solution used based on 
the cell concentrations used.   
The flexibility in choosing varying concentrations of GelMA to encapsulate cells allows control 
on properties like swelling and degradation of the hydrogel microspheres [62]. Also, there is 
control of parameters like viscosity and mechanical robustness of the used hydrogel 
concentrations. To support and hold the cells in place it is essential that they are seeded inside a 
support structure or a scaffold. Many times, cells do not get evenly seeded throughout the 
scaffold. The microspheres generated by this chip allow the creation of cell laden hydrogel 
emulsions which themselves serve as micron scale scaffolds. This can ensure adequate and even 
cell seeding all throughout the size of the injury or defect which needs the tissue engineered 
construct when a large number of these cell laden scaffolds can be injected for therapy. 
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 This engineered chip can potentially enable micro –scale encapsulation of all clinically relevant 
cell types in microspheres ranging 30 to 250 μm in size. Traditional tissue engineered constructs 
greater than 300μm in size have shown persistent challenges with oxygen and media diffusion, 
reflected in poor cell survival [2]. Due to the small size and range of encapsulation, effective 
media and oxygen diffusion is possible thereby showing enhanced cell viability. Additional 
procedural parameters are also controlled to ensure continued cell viability, ensuring no process-
induced loss.  
Rossow et.al had shown that micro encapsulation using PDMS devices fabricated using standard 
lithography approaches, led to microspheres 50 to 100 μm in mean diameter in which 86 out of 
100 microspheres were empty and only one microsphere should contain more than one cell [57].  
The small size of our resulting GelMA microspheres opens up the possibility for multiple clinical 
applications. Due to the small size of achieved emulsions, they are injectable, eliminating the 
need for invasive surgical procedures for their application. Most constructs must be 
cryopreserved until their time of use, a step which strongly hinders their viability [63]. This 
remains a major challenge in translating these macro-scaffolds into human clinical trials. To 
overcome some of these limitations, micro scale encapsulation can be used. In 
microencapsulation, the microspheres can be simply stored in media in a well plate in an 
incubator as the encapsulating hydrogel itself acts as a micron scale scaffold. Most crucially, 
however, traditional approaches require very rigid experimental setups to achieve successful 
microsphere formation and subsequent cell encapsulation.  
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It is also observed that this micro-scale encapsulation in hydrogel makes it a lot easier to 
preserve these micro-scale scaffolds in a normal well plate in an incubator instead of 
cryopreserving the construct. As an extension of this approach as a future application, we could 
potentially use these injectable microspheres in an animal model to study the growth of tissue 
engineered constructs in vivo and compare results with other research groups as we have better 
cell density per unit microsphere volume. 
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4.3 Conclusions 
Prolonged cell viability is a critical and poignant issue facing current tissue engineered 
constructs. This approach of cell micro encapsulation [64] using a non-clean room, 3D extrusion 
printing approach, serves as an inexpensive technique to make this happen. The dimensions of 
the microspheres allow them to be injectable and can be used as a way to avoid surgical opening 
up as required during implantation of other macro scale scaffolds. Even cell seeding throughout 
the tissue injury or defect is ensured due to the precise control over cell density as observed in 
vitro. The micro spherical shape of these cell laden constructs gives them good porosity and 
interconnectivity [65] when injected on top of each other. This could assist vascularization and 
ensure sustainability and efficient integration of the cells upon microsphere degradation. These 
microspheres have exhibited mechanical robustness and stability for up to 4 weeks with no 
visible degradation which makes them viable as scaffolds for tissue engineering applications 
with a potential to encapsulate clinically relevant cells. Reiterations of the experiments and 
viability studies have shown that this device is able to produce cell laden microspheres with 
minimal process induced damage. Moreover, the major advantage of this technology is the 
immense flexibility of experimental parameters that allows the use of all clinically relevant cell 
types for numerous types of tissue engineering applications. The use of 3D printing helps lower 
the barrier of entry to the use of microfluidic technology for other non-specific applications.
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Appendix A 
 
A. Supplementary Information  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 represents 10 μm Fluores-brite YG polyethylene fluorescence micro beads 
encapsulated in an emulsion of perfluorodecalin oil. This was an initial primary experiment to 
test the chip functionality and its ability to encapsulate micron scale samples. This image was 
taken using an inverted fluorescence microscope at 5X. This experiment demonstrated the 
efficiency and range of flow rates required to achieve bead encapsulation which by extension 
helped me figure out how to enable cell-encapsulation going further. Figure 14 (i) and (ii) show 
degrading non-cell laden 100 μm and cell laden microspheres on Day 27 and Day 29 
respectively. 
 
Figure 13. Fluores brite fluorescence beads encapsulated in an oil 
emulsion. Scale bar:100µm 
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We took bright field images of the microspheres for day 21 and day 27 to see how much they 
degrade over time. The onset of considerable degradation is seen post the three-week incubation 
period in PBS buffer for non-cell and DMEM media for cell-laden microspheres. The 
microspheres stayed stable for over 3 weeks with high cell viability. 
 
 
 
 
 
 
 
 
 
 
      
(i)                                                                      (ii) 
Figure 14. Degradation of a microsphere as observed on (i) Day 27 and (ii) Day 29 
respectively. Scale bar:100µm 
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B.
 
 
 
Scheme 5. The sketch represents our final microfluidic chip dimensions that were used to obtain 
all our results consistently. The change in this device design was mainly in its channel height. 
The goal of this work was to engineer a microfluidic device that can be used to engineer 
emulsion microsphere using a laminar flow of two immiscible phases. 
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C. Injection experiment with a 23-gauge needle: 
 
 
 
(A)                                                         (B) 
 
 
Figure 15 (A) Before and (B) After images 20x from injection of 100µm 8%w/v GelMA 
microspheres using a 23-gauge needle (Scale bar: 500µm) 
 
 
 
                                  (A)                                                                        (B) 
 
Figure 16 (A) Before and (B) After injection 5x 20µl emulsion of 100µm of 8%w/v GelMA 
using a 23-gauge needle (Scale bar: 500µm). 
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D. Swelling profile data details and variations observed 
 
 
Time 
(Minutes) 
Average % 
Change 
(Size 35) 
Average % 
Change 
(Size 50) 
Average % 
Change 
(Size 80) 
Average % 
Change 
(Size 100) 
Average % 
Change 
(Size 150) 
15 4.27 4.01 2.51 1.60 1.46 
30 7.93 7.21 4.07 2.93 2.36 
45 11.68 11.10 5.27 4.14 3.04 
60 14.93 15.56 6.93 5.26 3.94 
75 18.89 19.13 7.99 6.57 4.81 
90 24.60 24.24 10.08 8.30 5.38 
105 29.51 27.29 11.46 9.83 6.14 
120 38.05 30.08 12.71 11.84 6.93 
135 45.63 31.90 13.60 14.01 7.79 
150 50.01 34.07 13.60 15.33 8.48 
165 53.66 35.00 13.60 16.41 8.60 
180 54.95 35.01 13.60 16.54 8.60 
195 54.99 35.01 13.60 16.54 8.60 
210 54.99 35.01 13.60 16.54 8.60 
225 54.99 35.01 13.60 16.54 8.60 
 
Table 6. Average percentage increase in mean diameter of microspheres of different sizes 
(Swelling behavior) 
 
Time 
(Minutes) 
Standard 
Deviation 
%Change 
(Size 35) 
Standard 
Deviation 
%Change 
(Size 50) 
Standard 
Deviation 
%Change 
(Size 80) 
Standard 
Deviation 
%Change 
(Size 100) 
Standard 
Deviation 
%Change 
(Size 150) 
15 2.90 2.19 0.90 0.71 0.18 
30 3.76 1.97 0.58 0.76 0.24 
45 4.47 2.64 0.43 0.75 0.20 
60 5.45 4.31 0.61 0.55 0.45 
75 6.82 4.10 0.66 0.63 0.33 
90 3.51 5.33 0.82 0.82 0.43 
105 5.16 4.26 0.84 0.91 0.43 
120 8.62 3.90 0.82 1.19 0.29 
135 6.28 3.28 0.85 1.21 0.67 
150 5.09 4.54 0.85 0.95 0.72 
 
 
 
49 
165 3.00 4.80 0.85 0.63 0.80 
180 2.88 4.81 0.85 0.74 0.80 
195 2.95 4.81 0.85 0.74 0.80 
210 2.95 4.81 0.85 0.74 0.80 
225 2.95 4.81 0.85 0.74 0.80 
 
Table 7. Standard deviations in the corresponding percentage increase in mean sphere size 
observed. 
 
E. Statistical analysis for Viability data 
Data: Percentage Viability: Within group analysis using ANOVA-one way classification 
Day 1 Day 7 Day 14 Day 21 
99.3631 93.75 90.125 81.25 
99.3197 93.75 90.11 81.251 
99.5413 93.72 90.12 81.1457 
99.5495 93.73 90.125 81.25 
85.4167 93.79 90.2 81.252 
99.3827 93.75 90.125 81.246 
99.4398 93.75 90.125 81.25 
99.5614 93.75 90.11 81.245 
99.375 93.751 89.99 81.93 
99.4169 93.75 90.125 81.25 
 
Table 8. Percentage viability observed for n=10 emulsion samples for Day 1, Day 7, Day 14 and 
Day 21 
H0: There is no significant difference between the average percentage viability with respect to 
time (in Days) 
H1: Not H0 
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ANOVA 
Percentage Viability 
 
Sum of 
Squares 
Degrees 
of 
Freedom Mean Square F p-value 
Between 
Groups 
1516.519 3 505.506 102.531 .000 
Within Groups 177.491 36 4.930   
Total 1694.009 39    
 
Table 9. One way ANOVA analysis table 
 
Conclusion: Reject H0, since p-value < 0.05 (Level of Significance). Hence, there is a 
significant difference between Percent Viability with respect to time (in days). 
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Table 10. Bonferroni pair wise tests comparison of percentage viability as observed between 
different time points. 
Conclusion: 
1. There is a significant difference in the average percentage viability between Day1 and 
Day 7, Day 14 and Day 21. 
2. There is a significant difference in the average percentage viability between Day 7 and 
Day 14 and Day 21. 
3. There is a significant difference in the average percentage viability between Day 14 and 
Day 21. 
 
 
Multiple Comparisons 
Dependent Variable:   Percentage Viability   
Bonferroni  Test (Pair wise Tests) 
(I) Time In Days (J) Time In Days 
Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1 7 4.28751* .99300 .001 1.5151 7.0600 
14 7.92111* .99300 .000 5.1487 10.6936 
21 16.72964* .99300 .000 13.9572 19.5021 
7 1 -4.28751* .99300 .001 -7.0600 -1.5151 
14 3.63360* .99300 .005 .8612 6.4060 
21 12.44213* .99300 .000 9.6697 15.2146 
14 1 -7.92111* .99300 .000 -10.6936 -5.1487 
7 -3.63360* .99300 .005 -6.4060 -.8612 
21 8.80853* .99300 .000 6.0361 11.5810 
21 1 -16.72964* .99300 .000 -19.5021 -13.9572 
7 -12.44213* .99300 .000 -15.2146 -9.6697 
14 -8.80853* .99300 .000 -11.5810 -6.0361 
*. The mean difference is significant at the 0.05 level. 
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